Literature DB >> 20443921

Thrombotic microangiopathies: multimers, metalloprotease, and beyond.

Joel Moake1.   

Abstract

The pathophysiology of various types of thrombotic microangiopathies is coming progressively into focus. Therapeutic advances are likely to follow at a quickening pace. This discussion focuses on thrombotic thrombocytopenic purpura (TTP), the hemolytic-uremic syndrome (HUS), thrombotic microangiopathies associated with transplantation-immunosuppression or anti-angiogenesis therapy, and the preeclampsia/hemolysis-elevated liver enzymes and low platelets syndrome (HELLP).

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20443921      PMCID： PMC5350759          DOI： 10.1111/j.1752-8062.2009.00142.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN： 1752-8054            Impact factor:   4.689


  58 in total

1.  Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.

Authors:  Z Tao; K Anthony; Y Peng; H Choi; L Nolasco; L Rice; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2006-06-22       Impact factor: 5.824

2.  Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells.

Authors:  J A Frangos; J L Moake; L Nolasco; M D Phillips; L V McIntire
Journal:  Am J Physiol       Date:  1989-06

3.  Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers.

Authors:  Maneesh Arya; Bahman Anvari; Gabriel M Romo; Miguel A Cruz; Jing-Fei Dong; Larry V McIntire; Joel L Moake; José A López
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

4.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

5.  Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets.

Authors:  M D Phillips; J L Moake; L Nolasco; N Turner
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

Review 6.  Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).

Authors:  Anaadriana Zakarija; Hau C Kwaan; Joel L Moake; Nicholas Bandarenko; Dilip K Pandey; June M McKoy; Paul R Yarnold; Dennis W Raisch; Jeffrey L Winters; Thomas J Raife; John F Cursio; Thanh Ha Luu; Elizabeth A Richey; Matthew J Fisher; Thomas L Ortel; Martin S Tallman; X Long Zheng; Masanori Matsumoto; Yoshihiro Fujimura; Charles L Bennett
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

7.  Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymers.

Authors:  M Weinstein; E Vosburgh; M Phillips; N Turner; L Chute-Rose; J Moake
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

8.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Authors:  Valentina Bianchi; Rodolfo Robles; Lorenzo Alberio; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Protein phosphatase 2B inhibition promotes the secretion of von Willebrand factor from endothelial cells.

Authors:  L H Nolasco; F C Gushiken; N A Turner; T S Khatlani; S Pradhan; J-F Dong; J L Moake; K V Vijayan
Journal:  J Thromb Haemost       Date:  2009-03-27       Impact factor: 5.824

10.  Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).

Authors:  Barbara Plaimauer; Klaus Zimmermann; Dirk Völkel; Gerhard Antoine; Randolf Kerschbaumer; Pegah Jenab; Miha Furlan; Helen Gerritsen; Bernhard Lämmle; Hans Peter Schwarz; Friedrich Scheiflinger
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113
View more
  5 in total

1.  [Clinical course and differential diagnosis of thrombotic microangiopathy].

Authors:  M Guthoff; N Heyne
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-07-12       Impact factor: 0.840

Review 2.  Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.

Authors:  Trung C Nguyen; Miguel A Cruz; Joseph A Carcillo
Journal:  Crit Care Clin       Date:  2015-08-07       Impact factor: 3.598

Review 3.  Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).

Authors:  Sony Jacob; Brianne L Dunn; Zaina P Qureshi; Nicholas Bandarenko; Hau C Kwaan; Dilip K Pandey; June M McKoy; Sara E Barnato; Jeffrey L Winters; John F Cursio; Ivy Weiss; Thomas J Raife; Patricia M Carey; Ravindra Sarode; Joseph E Kiss; Constance Danielson; Thomas L Ortel; William F Clark; Gail Rock; Masanori Matsumoto; Yoshihiro Fujimura; X Long Zheng; Hao Chen; Fei Chen; John M Armstrong; Dennis W Raisch; Charles L Bennett
Journal:  Semin Thromb Hemost       Date:  2012-10-30       Impact factor: 4.180

4.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

Authors:  Erica Rurali; Federica Banterla; Roberta Donadelli; Elena Bresin; Miriam Galbusera; Sara Gastoldi; Flora Peyvandi; Mary Underwood; Giuseppe Remuzzi; Marina Noris
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

5.  ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.

Authors:  Galit Sarig
Journal:  Rambam Maimonides Med J       Date:  2014-10-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.